Colin P. N. Dinney, M.D.
Chairman of the Department of Urology
The University of Texas MD Anderson Cancer Center
Professor in the Division of Surgery
The University of Texas MD Anderson Cancer Center
B.S., University of Manitoba, Winnipeg, Canada Degree,
Microbiology, 1978
M.D., University of Manitoba, Winnipeg, Canada Degree,
Medicine, 1982
Board Certified, Fellowship of Royal College of
Physicians FRCP(S), 1989
Dr. Dinney is a Professor and Chairman of Urology. He maintains an active clinical practice
specializing in bladder cancer and a research laboratory focused on understanding the biology of
bladder cancer metastases and on the development of novel therapy for bladder cancer. His
group played a pioneering role in developing preclinical models of spontaneous bladder cancer
metastasis and used these models to identify the mechanisms regulating metastasis and for
preclinical therapeutic studies.
His group developed intravesical Nadoferigene Firadenovec (adenoviral-mediated interferon-α
gene therapy) for the treatment of BCG Unresponsive NMIBC. A Phase 3 trial was conducted by
the SUO-CTC. His laboratory is currently working to improve interferon gene therapy by
identifying biomarkers that predict sensitivity or resistance. These testing novel vectors might
improve transfection efficiency and activity and evaluating novel combination strategies.
Dr. Dinney served on the Society of Urologic Oncology Executive Committee, was the Founding
President of the SUO’s Clinical Trial Consortium, and is the current Chair of the SUO CTC
Bladder Cancer Committee. Dr. Dinney is the SPORE’s Liason to SWOG’s GU Executive
Committee. He is also a former member of the National Institutes of Health and Genitourinary
Steering Committee and served as the Urology Chair for the Bladder Cancer Task Force from
2016-2019.